Elsevier

Lung Cancer

Volume 60, Issue 2, May 2008, Pages 259-263
Lung Cancer

Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810)

https://doi.org/10.1016/j.lungcan.2007.09.018Get rights and content

Summary

Purpose

The purpose of this open-label phase II SWOG study was to evaluate the activity of gemcitabine (Gemzar®; Eli Lilly, Indiana, USA) and cisplatin combination therapy, in patients with unresectable malignant mesothelioma of the pleura.

Patients and methods

Fifty eligible chemotherapy naïve patients with histologically proven malignant mesothelioma of the pleura, and a SWOG performance status 0–2 were enrolled between February 1999 and August 2000. Treatment consisted of gemcitabine 1000 mg/m2 and cisplatin 30 mg/m2 on days 1, 8 and 15 of a 28-day cycle, until progression of disease or two cycles beyond complete response.

Results

Using SWOG response criteria, one patient had a confirmed complete response and five patients had a confirmed partial response, for a total response rate of 12% (95% CI 5–24%). All the responses were seen in patients with epithelioid or unspecified histology. Stable disease was seen in 25 patients (50%). The median overall survival was 10 months (95% CI 7–15 months), with a median progression-free survival of 6 months. Sixteen patients experienced Grade 4 toxicity. Twelve of these Grade 4 toxicities were hematologic. There were no treatment-related deaths.

Conclusions

Cisplatin–gemcitabine combination chemotherapy has modest activity with an acceptable toxicity profile, as first line treatment for patients with malignant mesothelioma.

Introduction

Malignant pleural mesothelioma (MPM) is an uncommon, neoplastic disorder of the pleural lining of the lung, usually presenting at an advanced stage and generally considered resistant to conventional chemotherapy treatment. The majority of cases (60–80%) occur in male patients, and are attributed to asbestos exposure, with a long latency between exposure and presentation [1], [2]. Although the incidence of the disease may have peaked in the United States, it continues to rise throughout much of the world where it is not expected to peak until sometime between 2010 and 2020 [3], [4].

The median survival of patients with unresectable MPM averages approximately 12 months [5], [6]. Numerous chemotherapy agents have been tested in phase II trials. Single agent chemotherapy has generally yielded response rates between 0 and 20%. Combination chemotherapy has resulted in somewhat higher response rates of 10–40% [7]. An impact on survival has been difficult to demonstrate until the recent phase III trials using cisplatin and the newer antifolates (i.e., pemetrexed and raltitrexed) which have now demonstrated a significant improvement in response rate and a survival advantage compared to cisplatin alone [5], [6].

In a murine mesothelioma model, gemcitabine has shown additive anti-tumor effects when administered in combination with cisplatin [8]. This combination was initially studied in Australia with promising results in MPM [9], [10]. In these studies cisplatin was administered at a dose of 100 mg/m2 on day 1, with gemcitabine at 1000 mg/m2 on days 1, 8 and 15 of a 28-day cycle. This Southwest Oncology Group (SWOG) study was designed to confirm and extend these results by using the same dose of gemcitabine, but dividing the cisplatin into three weekly doses to reduce the toxicity. The additional hypothesis was that this weekly dosing regimen might make allow greater synergism between the two agents.

Section snippets

Patients and methods

Between February 1999 and August 2000, 57 patients with unresectable MPM were enrolled onto this study at participating institutions from the SWOG. Patients were required to have histologically confirmed MPM of the pleura with bidimensionally measurable disease, SWOG performance status 0–2, and no prior chemotherapy or radiotherapy for any reason. Patients may have undergone prior surgery at least 4 weeks before study enrollment, and should have recovered from all side effects associated with

Results

Fifty-seven patients were registered on this study. Seven patients were found to be ineligible due to insufficient documentation of disease (two patients), inadequate baseline hematologic or renal function (three patients) and no measurable disease (two patients). Eleven patients were removed from protocol therapy before progression of disease, completion of treatment, or toxicity for reasons not specified in the protocol. This included worsening of disease not qualifying as disease progression

Discussion

This multicenter cooperative group study has failed to confirm the response rate seen with this combination in two prior trials in Australia [9], [10]. Although the response rates were lower, the median survival appears to be equivalent to the other trials. In the first single institution study by Byrne et al., 10 of the 21 enrolled patients (47%) exhibited a partial response. Nine of the 10 patients had epithelioid mesothelioma, and 1 patient had a mixed histology. The estimated median

References (17)

There are more references available in the full text version of this article.

Cited by (0)

This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA38926, CA32102, CA14028, CA35192, CA42777, CA20319, CA46441, CA35176, CA35128, CA67575, CA45807, CA35178, CA67663, CA63848, CA12213, CA58882, CA35262, CA35431, and supported in part by Eli Lilly and Company. Dr. Petrylak receives research funding for his clinical research from Eli Lilly and Company.

View full text